相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens
M. J. Lamas et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of the UGT1A1 and CYP2A6 Polymorphisms on Clinical Activity
Yoon Hee Choi et al.
ONCOLOGY (2012)
A Phase I Study of Infusional 5-Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan in Japanese Patients with Advanced Colorectal Cancer Who Harbor UGT1A1*1/*1, *1/*6 or *1/*28
Yu Sunakawa et al.
ONCOLOGY (2012)
Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis
Mafalda M. Dias et al.
PHARMACOGENOMICS (2012)
Clinical Implications of UGT1A1*28 Genotype Testing in Colorectal Cancer Patients
Katerina Shulman et al.
CANCER (2011)
UGT1A1*1/*28 and*1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer
Yu Sunakawa et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Prospective Phase II Study of FOLFIRI for mCRC in Japan, Including the Analysis of UGT1A1*28/*6 Polymorphisms
Yusuke Okuyama et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
B. Glimelius et al.
PHARMACOGENOMICS JOURNAL (2011)
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy
E. Martinez-Balibrea et al.
BRITISH JOURNAL OF CANCER (2010)
Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism
Shoichi Hazama et al.
CANCER SCIENCE (2010)
Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741
Howard L. McLeod et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05
Valerie Boige et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Meta-Analysis of Genome-wide Association Studies with Overlapping Subjects
Dan-Yu Lin et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2009)
Cost Effectiveness of Pharmacogenetic Testing for Uridine Diphosphate Glucuronosyltransferase 1A1 Before Irinotecan Administration for Metastatic Colorectal Cancer
Heather Taffet Gold et al.
CANCER (2009)
Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review
Glenn E. Palomaki et al.
GENETICS IN MEDICINE (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
UGT1A and Irinotecan Toxicity: Keeping It in the Family
Janelle M. Hoskins et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer
Christoph Schulz et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
E. Rouits et al.
BRITISH JOURNAL OF CANCER (2008)
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
D. M. Kweekel et al.
BRITISH JOURNAL OF CANCER (2008)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma
Chun-Yu Liu et al.
CANCER (2008)
Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer
Marko Obradovic et al.
PHARMACOGENOMICS (2008)
Methodological quality of pharmacogenetic studies: Issues of concern
Andrea L. Jorgensen et al.
STATISTICS IN MEDICINE (2008)
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy
A. Ruzzo et al.
PHARMACOGENOMICS JOURNAL (2008)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)
Insights, challenges, and future directions in irinogenetics
Tae Won Kim et al.
THERAPEUTIC DRUG MONITORING (2007)
UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan
Jean-Francois Cote et al.
CLINICAL CANCER RESEARCH (2007)
The role of pharmacogenetics in cancer therapeutics
Wei Peng Yong et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
Giuseppe Toffoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin
Ji-Youn Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy
C Massacesi et al.
CANCER (2006)
A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors
MA Wright et al.
CLINICAL CANCER RESEARCH (2005)
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
F Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications
A Premawardhena et al.
BLOOD CELLS MOLECULES AND DISEASES (2003)
Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance
JO Miners et al.
TOXICOLOGY (2002)
Camptothecins - A review of their chemotherapeutic potential
H Ulukan et al.
DRUGS (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis
S Duval et al.
BIOMETRICS (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
